Raul Cordoba: End points in clinical trials in diffuse large B-cell lymphoma
Raul Cordoba shared on X:
“Hematology End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?”
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Authors: Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, Aby Buchbinder, Marc Buyse, Miriam Fuchs, Susan Halabi, Robert Hemmings, Aisha Masood, Simon Newsome, Claire Saxton, Lorna Warwick, Nigel A Yateman, Emmanuel Zuber
More posts featuring Raul Cordoba on oncodaily.com
Raúl Córdoba Mascuñano, MD, PhD is a specialist in hematology and hemotherapy. He is the Chair of Community Stakeholder Committee at European Hematology Association (EHA) and Coordinator of the Lymphoma Unit and Associate Chief of Hematology Department at Jiménez Díaz Foundation. He is the principal investigator for numerous clinical trials for non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia and other chronic lymphoproliferative syndromes. He is a member of the ethical review board at his current workplace.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023